Devon Medical Marijuana Startup Zynerba Pharmaceuticals Set To Go Public

By

Vista Today
Allison Gilmer Vista TOday Chester County Business News
The PA Department of Health has released temporary regulations to guide the start of medical marijuana production and distribution.

A synthetic medical marijuana pioneer recently transplanted in Devon is experiencing an exciting high this week as it prepares to go public with 10 years worth of development and two promising therapy candidates.

Zynerba Pharmaceuticals is set to launch its $51.75 million initial public offering next week; the 3.45 million shares of common stock are expected to sell for $13 to $15 each, according to a Philadelphia Business Journal report.

Armando Anido, CEO of
Armando Anido, CEO of Zynerba.

IPO proceeds will help the 10-year-old firm further develop pain relief therapies for sufferers of epilepsy, fibromyalgia, peripheral neuropathic pain and other health conditions.

Currently its synthetic therapies are designed to be delivered through a patch and a gel. Zynerba will seek regulatory approval from the U.S. Food and Drug Administration, with human clinical testing anticipated to begin in late 2015 and mid-2016.

The company was brought to Chester County to benefit from new CEO Armando Anido,  who led Malvern-based NuPathe and Chesterbrook-based Auxilium before they were acquired by Teva Pharmaceuticals and Endo International, respectively.

Read more about the coming IPO in the Philadelphia Business Journal here.

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo